Download presentation
Presentation is loading. Please wait.
Published byJanice Glenn Modified over 9 years ago
1
Pam Charity, MD Cathryn Caton, MD, MS
2
Define pneumonia Review criteria for diagnosis Review criteria for admission Review treatment options
3
Fever Leukocytosis Infiltrate on CXR
4
History Physical Exam Laboratory Data Radiographic findings
5
Severity of Illness Scores – CURB-65 (confusion, uremia, respiratory rate, low blood pressure, age 65 or greater) Consider other factors – ability to safely and reliably take oral medication, support resources CURB-65 > or = 2, more intensive treatment
6
Major criteria Septic shock requiring vasopressors Acute respiratory failure requiring intubation and mechanical ventilation Minor Criteria Respiratory rate >30 PaO2/FiO2 ratio <250 Multilobar infiltrates Confusion BUN >20 Leukopenia, thrombocytopenia Hypothermia
7
Healthy and no risk factors for drug resistant S. Pneumoniae Macrolide – azithromycin Doxycycline
8
Patients with co-morbid conditions – chronic heart, lung, renal disease; DM; ETOH; malignancies; asplenia; immunosuppressing drugs use of abx within last 3 months or other risk for drug resistant S. Pneumoniae Then use fluoroquinolone B – Lactam plus macrolide or amoxicillin-clavulanate
9
Fluoroquinolone B-Lactam plus a macrolide First dose of antibiotics should be administered in the ED after blood cultures are obtained.
10
B-Lactam plus either azithromycin or a fluoroquinolone For pseudomonas use B-Lactam plus fluoroquinolone or B-Lactam plus an aminoglycoside and azithromycin or B-Lactam plus an aminoglycoside and a fluoroquinolone
11
Patients should be switched when Hemodynamically stable Clinically improving Able to tolerate oral medications Patients should be discharged as soon as clinically stable without other active issues
12
Minimum of 5 days Afebrile for 48-72 hours No more than 1 CAP associated sign of clinical instability
13
IDSA / ATS Guidelines Clinical Infectious Diseases 2007; 44:S27-72
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.